The pharmacology of letrozole (Q35589740)

9 August 2017

1 reference

title

The pharmacology of letrozole (English)

1 reference

9 August 2017

1 reference

Haynes BP

1

1 reference

9 August 2017

Dowsett M

2

1 reference

9 August 2017

Miller WR

3

1 reference

9 August 2017

Dixon JM

4

1 reference

9 August 2017

Bhatnagar AS

5

1 reference

9 August 2017

publication date

1 October 2003

1 reference

The Journal of Steroid Biochemistry and Molecular Biology

9 August 2017

published in

1 reference

9 August 2017

volume

87

1 reference

9 August 2017

issue

1

1 reference

9 August 2017

page(s)

35-45

1 reference

Letrozole, a new oral aromatase inhibitor for advanced breast cancer: double-blind randomized trial showing a dose effect and improved efficacy and tolerability compared with megestrol acetate

9 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

A randomised trial comparing two doses of the new selective aromatase inhibitor anastrozole (Arimidex) with megestrol acetate in postmenopausal patients with advanced breast cancer.

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Exemestane is superior to megestrol acetate after tamoxifen failure in postmenopausal women with advanced breast cancer: results of a phase III randomized double-blind trial. The Exemestane Study Group.

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: evidence from a phase III randomized trial

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: results of a phase III study of the International Letrozole Breast Cancer Group

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy in hormone receptor positive advanced breast carcinoma

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Aromatase inhibitors: synthesis, biological activity, and binding mode of azole-type compounds

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Structure-activity relationships and binding model of novel aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Plasma protein binding of letrozole, a new nonsteroidal aromatase enzyme inhibitor

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Absolute bioavailability of letrozole in healthy postmenopausal women

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Comparative bioavailability of letrozole under fed and fasting conditions in 12 healthy subjects after a 2.5 mg single oral administration

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Effect of age and single versus multiple dose pharmacokinetics of letrozole (Femara) in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Biology of aromatase inhibitors: pharmacology/endocrinology within the breast

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Highly selective inhibition of estrogen biosynthesis by CGS 20267, a new non-steroidal aromatase inhibitor

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Intracellular aromatase and its relevance to the pharmacological efficacy of aromatase inhibitors

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

The steroidal antiestrogen ICI 182,780 is an inhibitor of cellular aromatase activity

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

The effect of combining aromatase inhibitors with antiestrogens on tumor growth in a nude mouse model for breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Detection of aromatase inhibitors in vitro using rat ovary microsomes

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Anti-tumor and endocrine effects of non-steroidal aromatase inhibitors on estrogen-dependent rat mammary tumors.

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

The role of estrogen in the feedback regulation of follicle-stimulating hormone secretion in the female rat

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Effect of CGS 20267 on ovarian aromatase and gonadotropin levels in the rat

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

An in vivo model of intratumoural aromatase using aromatase‐transfected MCF7 human breast cancer cells

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

The effects of aromatase inhibitors and antiestrogens in the nude mouse model

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Aromatase overexpression and breast hyperplasia, an in vivo model--continued overexpression of aromatase is sufficient to maintain hyperplasia without circulating estrogens, and aromatase inhibitors abrogate these preneoplastic changes in mammary gl

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Aromatase inhibitors prevent spontaneous granular cell tumors in the distal female reproductive tract of Sprague-Dawley rats

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Letrozole (CGS 20267). A phase I study of a new potent oral aromatase inhibitor of breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Effects of Fadrozole (CGS 16949A) and Letrozole (CGS 20267) on the inhibition of aromatase activity in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

The influence of aminoglutethimide and its analogue rogletimide on peripheral aromatisation in breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

The influence of intramuscular 4-hydroxyandrostenedione on peripheral aromatisation in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

The influence of CGS 16949A on peripheral aromatisation in breast cancer patients

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Influence of anastrozole (Arimidex), a selective, non-steroidal aromatase inhibitor, on in vivo aromatisation and plasma oestrogen levels in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Mechanism for maintenance of high breast tumor estradiol concentrations in the absence of ovarian function: role of very high affinity tissue uptake

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

In situ estrogen production via the estrone sulfatase pathway in breast tumors: relative importance versus the aromatase pathway

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Local endocrine effects of aromatase inhibitors within the breast

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Biological and clinical effects of aromatase inhibitors in neoadjuvant therapy

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Pharmacokinetics of anastrozole and tamoxifen alone, and in combination, during adjuvant endocrine therapy for early breast cancer in postmenopausal women: a sub-protocol of the 'Arimidex and tamoxifen alone or in combination' (ATAC) trial

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Inhibitors of steroidogenic enzymes for the treatment of breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Effect of estrogen deprivation on the reproductive physiology of male and female primates

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Use of an aromatase inhibitor for induction of ovulation in patients with an inadequate response to clomiphene citrate

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Double-blind, randomised, multicentre endocrine trial comparing two letrozole doses, in postmenopausal breast cancer patients1Accepted as a poster presentation to the 34th Annual Meeting of the American Society of Clinical Oncology, May 1998, Los Ang

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Letrozole, a new oral non-steroidal aromastase inhibitor in treating postmenopausal patients with advanced breast cancer. A pilot study

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Comparison of the Low Dose Short Synacthen Test (1 g), the Conventional Dose Short Synacthen Test (250 g), and the Insulin Tolerance Test for Assessment of the Hypothalamo-Pituitary-Adrenal Axis in Patients with Pituitary Disease

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Establishment of reference values for standard dose short synacthen test (250 microgram), low dose short synacthen test (1 microgram) and insulin tolerance test for assessment of the hypothalamo-pituitary-adrenal axis in normal subjects

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

The short Synacthen and insulin stress tests in the assessment of the hypothalamic-pituitary-adrenal axis

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

The use of the short tetracosactrin test for the investigation of suspected pituitary hypofunction

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Role of low levels of endogenous estrogen in regulation of bone resorption in late postmenopausal women

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

Effect of letrozole on the lipid profile in postmenopausal women with breast cancer

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

The aromatase inhibitor letrozole in advanced breast cancer: Effects on serum insulin-like growth factor (IGF)-I and IGF-binding protein-3 levels

1 reference

https://api.crossref.org/works/10.1016/S0960-0760(03)00384-4

7 January 2021

10.1016/S0960-0760(03)00384-4

Identifiers

DOI

1 reference

9 August 2017

1 reference